First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

Abstract Background ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study ( NCT01284192 ) assessed the safety, pharmacokinetic profile, a...

Full description

Bibliographic Details
Main Authors: Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony Tolcher
Format: Article
Language:English
Published: BMC 2016-03-01
Series:Journal of Hematology & Oncology
Subjects:
ASP3026
Neoplasms
ALK inhibitor
Phase I
Pharmacokinetics
Online Access:http://link.springer.com/article/10.1186/s13045-016-0254-5

Internet

http://link.springer.com/article/10.1186/s13045-016-0254-5

Similar Items